Statistical analysis
AML
The primary objective of this study was to evaluate the safety and determine the RP2D of milademetan (Phase I) and efficacy (by ELN 2017 criteria – Phase 2) of the combination therapy in both frontline and R/R AML patient population. Secondary and exploratory objectives are detailed in the supplemental study protocol.